Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

G9a-like protein (human recombinant)

  • Zoom
    G9a-<wbr/>like protein (human recombinant)
  • G9a-<wbr/>like protein (human recombinant)
Cat No: 10755
Proteins - Enzymes
Cayman

Post-translational modification of histones by methylation of lysine residues can promote transcriptional activation or repression. G9a-like protein (GLP) and G9a are SET domain-containing methyltransferases that specifically mono- and di-methylate hi...

More
: 50 µg

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Correlated keywords:
  • lysine methylation methyltransferase genes silencing repression SET domain histones modifications GLP H3K9 BIX-01294 UNC0638 inhibitors inhibits inhibition SAR monomethylate dimethylate BIX01294 BIX 01294 UNC-0638 UNC 0638 active
Product Overview:
Post-translational modification of histones by methylation of lysine residues can promote transcriptional activation or repression. G9a-like protein (GLP) and G9a are SET domain-containing methyltransferases that specifically mono- and di-methylate histone H3 at lysine 9 (H3K9).{19158,19156} Methylation of H3K9 by a GLP/G9a heteromeric complex regulates gene expression by silencing euchromatin.{19160} GLP and G9a share 80% sequence identity in their SET domains. Structure-activity relationship (SAR) studies have been employed to design potent and selective inhibitors of these proteins, including BIX-01294 and UNC0638, with IC50 values in the nanomolar range.{18376}
Size 50 µg
Shipping dry ice
Purity ≥95% estimated by SDS-PAGE
Custom Code 3504.00
UNSPSC code 12352204

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

/ We also advise you

Cross selling for this product : G9a-<wbr/>like protein (human recombinant) There are 10 products.

Search